Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01816776 · ClinicalTrials.gov registry record · NA
Respicardia, Inc. Pivotal Trial of the remedē System
A NA study, sponsored by Respicardia.
- Completed
- Registry status
- NA
- Development phase
- 151
- Enrollment target
NCT01816776 is a NA study that has completed, run by Respicardia. The registered enrollment target is 151 participants.
The verdict
NCT01816776, a NA study, has completed, sponsored by Respicardia.
- COMPLETED
- Registry status
- NA
- Development phase
- 151 participants
- Enrollment target
Study Summary
The primary purpose of this prospective, multicenter, randomized trial is to evaluate the safety and effectiveness of therapy delivered by the remedē® system in subjects with moderate to severe central sleep apnea and optimal medical management, compared to outcomes in randomized control subjects receiving optimal medical management and implanted but inactive remedē® systems.
Interventions
- DEVICE Treatment Group (transvenous stimulation of the phrenic nerve)
- DEVICE Control Group (Optimal Medical Therapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 151 participants |
| Start Date | 2013-03 |
| Est. Completion | 2017-11-07 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01816776
The ClinicalTrials.gov registry entry for NCT01816776 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 151 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Respicardia, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Treatment Group (transvenous stimulation of the phrenic nerve) is the first listed.
NCT01816776 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01816776 about?
NCT01816776 is a clinical study titled "Respicardia, Inc. Pivotal Trial of the remedē System". The primary purpose of this prospective, multicenter, randomized trial is to evaluate the safety and effectiveness of therapy delivered by the remedē® system in subjects with moderate to severe central sleep apnea and optimal medical management, compared to outcomes in randomized control subjects re...
What is the current status of trial NCT01816776?
This trial is currently completed. It is a NA study. The enrollment target is 151 participants. The study started on 2013-03. Estimated completion is 2017-11-07.
What interventions are being tested in trial NCT01816776?
The interventions under investigation include: Treatment Group (transvenous stimulation of the phrenic nerve) (DEVICE), Control Group (Optimal Medical Therapy) (DEVICE).
Who is sponsoring clinical trial NCT01816776?
This trial is sponsored by Respicardia, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.